0001682852-26-000033
SEC filingModerna, Inc. reported a net loss of $2.82 billion for fiscal year 2025, driven by a significant operating loss of $3.07 billion. Total revenue for the year was $1.94 billion, while total operating expenses reached $5.02 billion, with research and development costs accounting for $3.13 billion of that total. The company maintained a strong liquidity position with $2.60 billion in cash and cash equivalents and $3.20 billion in investments, resulting in total current assets of $6.54 billion. Cash flow from operations was negative $1.87 billion, but this was offset by $1.95 billion in net cash provided by investing activities and $593 million from financing activities, leading to a net increase in cash of $668 million. The company ended the year with total assets of $12.34 billion and stockholders' equity of $8.65 billion.
Moderna, Inc. reported challenging financial results for fiscal year 2025, with a net loss of $2.82 billion. The company generated total revenue of $1.94 billion but faced substantial operating expenses totaling $5.02 billion, resulting in an operating loss of $3.07 billion. Research and development expenses were particularly significant at $3.13 billion, representing the largest component of operating costs. The company's cost of sales was $868 million, while selling, general and administrative expenses totaled $1.02 billion. Interest income provided some offset at $314 million, but other expenses netted to $8 million in losses. The company recorded a tax provision of $54 million despite the pre-tax loss of $2.77 billion.
Total revenue for fiscal year 2025 was $1.94 billion. The XBRL data does not provide segment breakdowns, geographic mix, or specific growth drivers for the revenue. The document content similarly lacks detailed revenue segmentation or analysis of revenue composition. Without explicit disclosure of segment performance or geographic distribution in the provided data, no further breakdown can be provided.
The company reported negative operating margins due to the operating loss of $3.07 billion on revenue of $1.94 billion. Gross profit cannot be calculated from the provided data as only total revenue and cost of sales are disclosed without a clear gross profit figure. The cost structure shows research and development as the largest expense category at $3.13 billion, followed by selling, general and administrative expenses at $1.02 billion, and cost of sales at $868 million. The company's net loss per share was $7.00 for both basic and diluted calculations.
Cash flow from operating activities was negative $1.87 billion, primarily driven by the net loss of $2.82 billion, partially offset by non-cash adjustments including stock-based compensation of $483 million and depreciation and amortization of $215 million. Investing activities provided $1.95 billion in net cash, mainly from proceeds from maturities and sales of marketable securities exceeding purchases. Financing activities contributed $593 million in net cash, primarily from proceeds from a credit facility. The balance sheet shows strong liquidity with $2.60 billion in cash and cash equivalents and $3.20 billion in investments. Total assets were $12.34 billion, with current assets of $6.54 billion. Total liabilities were $3.69 billion, resulting in stockholders' equity of $8.65 billion.
The provided XBRL data and document content do not include management guidance, strategic priorities, or specific risk factors for future periods. No forward-looking statements, outlook commentary, or strategic initiatives are disclosed in the financial data sections provided. The analysis is limited to the historical financial results for fiscal year 2025 as presented in the XBRL data.